Mepolizumab (anti-IL5)

• CAT Number: I040137
• CAS Number: 196078-29-2
• Purity: ≥95%

Mepolizumab (Cat No.: I040137) is a humanized monoclonal antibody targeting interleukin-5 (IL-5), a key cytokine involved in the growth, activation, and survival of eosinophils. By binding to IL-5, mepolizumab prevents its interaction with IL-5 receptors, reducing eosinophil levels and inflammation. It is approved for treating eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). Administered via subcutaneous injection, mepolizumab helps decrease exacerbation frequency and improve respiratory function, offering a targeted approach for managing eosinophil-driven inflammatory diseases.

Reference

[1]. Tim Harrison, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151.
[Content Brief]

[2]. Ian D Pavord, From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases. Allergy. 2022 Mar;77(3):778-797.
[Content Brief]